{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Jennifer S Walsh, Richard Jacques, Lutz Schomburg, Tom Hill, John Mathers, Graham Williams & Richard Eastell.

Jennifer S Walsh ^1,*, Richard Jacques ², Lutz Schomburg ³, Tom Hill ⁴, John Mathers ⁴, Graham Williams ⁵, Richard Eastell ¹

¹ Mellanby Centre for Bone Research, University of Sheffield, Northern General Hospital, Sheffield, UK
² School of Health and Related Research, University of Sheffield, Sheffield, UK
³ Institut für Experimentelle Endokrinologie, Berlin, Germany
⁴ Human Nutrition Research Centre, Newcastle University, Newcastle upon Tyne, UK
⁵ Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
^* Corresponding author Email: j.walsh@sheffield.ac.uk

Declared competing interests of authors: Jennifer S Walsh reports grants from the National Institute for Health Research (NIHR), personal fees from Mereo BioPharma (London, UK), personal fees and non-financial support from Eli Lilly and Company (Indianapolis, IN, USA), personal fees from Sandoz (Holzkirchen, Germany), grants from Alexion Pharmaceuticals (Boston, MA, USA), and personal fees from UCB Pharma (Brussels, Belgium), Pharmacosmos (Holbæk, Denmark) and Kyowa Kirin International (Galashiels, UK). Lutz Schomnburg holds shares of selenOmed GmbH (Berlin, Germany), a company involved in selenium status assessment. Tom Hill received personal fees from the Dairy Council GB, and grants from Nutricia (Liverpool, UK). Richard Eastell reports grants from NIHR during the conduct of the study. He also reports grants and personal fees from IDS, Roche Diagnostics Ltd (Burgess Hill, UK) and Nittobo (Tokyo, Japan), personal fees from GSK Nutrition (Brentford, UK), the Foundation for the National Institutes of Health (North Bethesda, MA, USA), Mereo BioPharma, Eli Lilly and Company, Sandoz, personal fees from AbbVie (North Chicago, IL, USA), Samsung Group (Seoul, Republic of Korea), Haoma Medical (London, UK), CLBiO Co., Ltd (Secho-gu, Republic of Korea), Biocon (Bengaluru, India), Lyramid (Sydney, NSW, Australia), and Viking Therapeutics (CA, USA), and grants from Amgen (Thousand Oaks, CA, USA) and Alexion Pharmaceuticals outside the submitted work.